For more than two decades ThermoGenesis Holdings, Inc. has developed and commercialized novel cell processing systems and devices providing global researchers, biomanufacturing organizations and clinicians with highly efficient cell processing devices which helped them to deliver better outcomes in various applications in the cell and gene therapy field.
We offer closed automated solutions for manual steps in the cell manufacturing process. Our flexible automated modules provide performance gains in purifying mononuclear cells, washing contaminants from cell fractions, cell selection, and storage while significantly shortening processing times.
Cell separation is an essential part of the manufacturing process for CGT cell therapies like CAR-T. To get the best results, cell samples must be purified and prepared properly. Purifying cells is achieved by a different approaches (positive selection, negative selection, etc.) which all can use different methodologies to accomplish their goals. Some of the … Continued
Conference Call to be Held Today at 1:30 p.m. PT/4:30 p.m. ET RANCHO CORDOVA, Calif., November 12, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2021 … Continued
Cell and gene therapy is growing and new therapies are rapidly evolving , leading to an increase in the demand for efficient and effective cell therapy manufacturing. Each step in the process must be meticulously carried out in order to achieve the best possible results, increasing the likelihood of effectiveness for certain therapies. This begins … Continued
Conference Call to be Held on November 12, 2021 RANCHO CORDOVA, Calif., November 5, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the third quarter ended September 30, 2021 … Continued
Personalized treatments are the wave of the future in medicine. With regenerative medicine treatments like CAR-T cell therapy receiving FDA approval, the demand for the manufacturing of cell therapies is only going to continue to grow. However, there are unique logistical challenges in the cell therapy manufacturing process that are preventing these treatments from becoming … Continued
Cell-based therapies are growing in popularity and are in higher demand, creating a need for scalability in manufacturing. There are several challenges associated with the mass production of cell therapies, the most concerning of which being the safety and efficacy of the manufacturing process to ensure patients are receiving the highest-quality treatment. Utilizing automated, … Continued